Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3283142 Safety and PK in Chinese Healthy Participants
NCT06487845Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BAY3283142 in chronic kidney disease (CKD) (3 arms), sponsored by Bayer. Primary endpoints: Number of participants with treatment emergent adverse event up to 25 days and Percentage of participants with treatment emergent adverse event up to 25 days. Started Jul 2024; status: completed.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06487845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487845.